Albert David Limited (NSE:ALBERTDAVD)
750.60
-19.70 (-2.56%)
Dec 15, 2025, 3:29 PM IST
Albert David Revenue
Albert David had revenue of 872.41M INR in the quarter ending September 30, 2025, a decrease of -11.37%. This brings the company's revenue in the last twelve months to 3.16B, down -13.51% year-over-year. In the fiscal year ending March 31, 2025, Albert David had annual revenue of 3.46B, down -4.61%.
Revenue (ttm)
3.16B
Revenue Growth
-13.51%
P/S Ratio
1.36
Revenue / Employee
1.75M
Employees
1,805
Market Cap
4.29B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Mar 31, 2025 | 3.46B | -166.94M | -4.61% |
| Mar 31, 2024 | 3.62B | 208.97M | 6.12% |
| Mar 31, 2023 | 3.42B | 280.53M | 8.95% |
| Mar 31, 2022 | 3.14B | 660.62M | 26.70% |
| Mar 31, 2021 | 2.47B | -733.45M | -22.86% |
| Mar 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Sun Pharmaceutical Industries | 549.64B |
| Aurobindo Pharma | 325.14B |
| Cipla | 279.66B |
| Zydus Lifesciences | 244.94B |
| Apollo Hospitals Enterprise | 232.65B |
| Glenmark Pharmaceuticals | 159.97B |
| Alkem Laboratories | 138.90B |
| Mankind Pharma | 135.46B |